A biopharmaceutical company that chooses, develops, and markets medicines is Gilead Company, created by Riordan.
The company's main focus is on the antiviral medications Harvoil and Sovalid, which are used to treat cancer, HIV/AIDS, and liver illnesses. FDA has authorized the use of the business' products to treat the aforementioned ailments.
However, Miles White serves as the CEO of the pharmaceutical company AbbVie.
Both biopharmaceuticals and small molecule medications are the company's primary areas of research, development, and marketing. In 2013, spin-off laboratories were the cause of its creation. Both businesses have a medicine that treats an unusual sickness in a viable market, and they charging over $ 16,000/pill in aid of treating the disease is morally wrong, the patient's dignity should be considered above any return estimations.
The choice of adopting the price reduction in the two companies will create a significant difference depending on their preference for the consideration that the drugs have demonstrated a noticeable progress in health.
The CEO of Gilead company will not be affected by the price reduction of the drug to $40/pill as the company has repaid its initial investment repeatedly due to substantial portfolio utilization in risk diversification hence no impact in material endurance. However, the sum of proceeds obtainable for new drug research will show a significant impact. On the other hand, AbbVie Company adopting the price reduction will suffer a substantial loss of the profits made and also the growth of the business is at risk since more time is needed to repay the capital investment.
Although Company risk should not be a guiding factor for a prospective societal benefit, the CEO's should consider the recompense of tapping into the broader treatment market.
There is also the fact that the competition is stiff and the various incumbent cures even though there is no guarantee of acceptance of these drugs in the market. Also having been no time and statistics for the medicines to avert their superior outcome, the companies' best choice should be to take the FDA price.
